 SAN DIEGO, May 12, 2021 GLOBE NEWSWIRE -- Obalon Therapeutics, Inc. NASDAQ:OBLN, a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the first quarter ended March 31, 2021. On January 19, 2020 the Company signed a definitive agreement for a merger with ReShape Lifesciences Inc. 